Last reviewed · How we verify
FP
FP is a fluorinated propellant and surfactant used as a metered-dose inhaler (MDI) propellant in respiratory drug formulations.
At a glance
| Generic name | FP |
|---|---|
| Also known as | fluticasone propionate |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Drug Delivery |
| Phase | FDA-approved |
Mechanism of action
FP typically refers to hydrofluoroalkane (HFA) propellants, specifically HFA-134a or HFA-227, which replaced chlorofluorocarbon (CFC) propellants due to ozone-depletion concerns. These propellants enable aerosolization and delivery of active pharmaceutical ingredients to the lungs via pressurized MDI devices. FP itself has no direct pharmacological activity but is essential for drug delivery.
Approved indications
Common side effects
Key clinical trials
- The Effectiveness of Neurodevelopmental Treatment (Bobath) and Functional Physiotherapy in Children With Cerebral Palsy. (NA)
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (PHASE3)
- A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). (PHASE1, PHASE2)
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (PHASE3)
- The RAFT ECT Study (NA)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
- A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FP CI brief — competitive landscape report
- FP updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI